Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development
暂无分享,去创建一个
[1] Wei Zhang,et al. Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients , 2007, Acta Pharmacologica Sinica.
[2] H. Greim,et al. Uptake of taurocholic acid into isolated rat-liver cells. , 1975, European journal of biochemistry.
[3] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[4] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[5] H. Kusuhara,et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. , 2004, Drug metabolism and pharmacokinetics.
[6] Yuichi Sugiyama,et al. Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.
[7] P. Taylor,et al. Current progress on esterases: from molecular structure to function. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[8] H. Strobel,et al. Extrahepatic drug metabolizing enzymes , 1999, Journal of biochemical and molecular toxicology.
[9] J. Houston,et al. PREDICTION OF METABOLIC CLEARANCE USING CRYOPRESERVED HUMAN HEPATOCYTES: KINETIC CHARACTERISTICS FOR FIVE BENZODIAZEPINES , 2005, Drug Metabolism and Disposition.
[10] D. Oh,et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers , 2005, Clinical pharmacology and therapeutics.
[11] R. Riley,et al. The pivotal role of hepatocytes in drug discovery. , 2007, Chemico-biological interactions.
[12] Nicola J Hewitt,et al. Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum‐free incubations , 2006, The Journal of pharmacy and pharmacology.
[13] D. Jaeck,et al. Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[14] D. Keppler,et al. Vectorial Transport of the Peptide CCK-8 by Double-Transfected MDCKII Cells Stably Expressing the Organic Anion Transporter OATP1B3 (OATP8) and the Export Pump ABCC2 , 2005, Journal of Pharmacology and Experimental Therapeutics.
[15] J Brian Houston,et al. Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.
[16] T. Kennedy. Managing the drug discovery/development interface , 1997 .
[17] R. Kim,et al. Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.
[18] J. Houston,et al. Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[19] L Fritsche,et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.
[20] B. Telfer,et al. Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[21] Yuichi Sugiyama,et al. Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.
[22] J. Houston,et al. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. , 1987, Drug metabolism and disposition: the biological fate of chemicals.
[23] G. Tucker,et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[24] Y. Sugiyama,et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.
[25] R. Obach,et al. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[26] M. Rowland,et al. Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model , 1986, The Journal of pharmacy and pharmacology.
[27] J B Houston,et al. Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[28] Kiyomi Ito,et al. Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches , 2004, Pharmaceutical Research.
[29] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[30] P. Olinga,et al. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. , 1998, The Journal of pharmacology and experimental therapeutics.
[31] Michael S. Roberts,et al. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations , 1986, Journal of Pharmacokinetics and Biopharmaceutics.
[32] I. Phillips,et al. Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. , 1996, European journal of biochemistry.
[33] Teruko Imai,et al. Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine , 2006, Drug Metabolism and Disposition.
[34] J B Houston,et al. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[35] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[36] A. Galetin,et al. Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[37] Wei Zhang,et al. SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. , 2007, British journal of clinical pharmacology.
[38] R. Obach. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[39] U. Christians,et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[40] P. Neuvonen,et al. Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.
[41] Y. Sugiyama,et al. Drug transporters: their role and importance in the selection and development of new drugs. , 2002, Drug metabolism and pharmacokinetics.
[42] Aleksandra Galetin,et al. UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.
[43] G. L. Kedderis,et al. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. , 1999, Chemico-biological interactions.
[44] Xinxin Ding,et al. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.
[45] K. Maeda,et al. Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.
[46] K. Pang,et al. THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING , 2005, Drug Metabolism and Disposition.
[47] Teruko Imai,et al. Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.
[48] J. Tuszynski,et al. Reassessing Models of Hepatic Extraction , 2003, Journal of biological physics.
[49] Robert J Riley,et al. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. , 2003, British journal of clinical pharmacology.
[50] H. Kusuhara,et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. , 2003, Drug metabolism and pharmacokinetics.
[51] Chuang Lu,et al. Comparison of Intrinsic Clearance in Liver Microsomes and Hepatocytes from Rats and Humans: Evaluation of Free Fraction and Uptake in Hepatocytes , 2006, Drug Metabolism and Disposition.
[52] Albert P. Li,et al. Human hepatocytes: isolation, cryopreservation and applications in drug development. , 2007, Chemico-biological interactions.
[53] Kazuya Maeda,et al. CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS , 2005, Drug Metabolism and Disposition.
[54] D. Eaton,et al. Uptake of morphine and nalorphine by isolated rat hepatocytes. , 1978, The Journal of pharmacology and experimental therapeutics.
[55] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[56] K. Nagata,et al. Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: Comparison among well-stirred, parallel-tube, distributed and dispersion models , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[57] Andrew Rowland,et al. Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation , 2007, Journal of Pharmacology and Experimental Therapeutics.
[58] R. Weisiger. Dissociation from albumin: a potentially rate-limiting step in the clearance of substances by the liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[59] A. Li,et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. , 1999, Chemico-biological interactions.
[60] Mikko Niemi,et al. Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.
[61] Ken Grime,et al. Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo , 2007, Drug Metabolism and Disposition.
[62] D. Keppler,et al. Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells , 2005, Molecular Pharmacology.
[63] Malcolm Rowland,et al. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[64] Y. Sawada,et al. Dose-dependent hepatic handling of l-propranolol determined by multiple indicator dilution method: influence of tissue binding of l-propranolol on its hepatic elimination. , 1993, Biological and Pharmaceutical Bulletin.
[65] A. El-Kadi,et al. Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[66] Masato Chiba,et al. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[67] U. Hofmann,et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.
[68] U. Klotz,et al. Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.
[69] J. Houston,et al. Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[70] Yuichi Sugiyama,et al. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[71] Kazuya Maeda,et al. In Vitro–In Vivo Scale‐up of Drug Transport Activities , 2006 .
[72] F. Oesch,et al. Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[73] A. Rettie,et al. Immunoquantitation of FMO1 in human liver, kidney, and intestine. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[74] J B Houston,et al. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.
[75] P. Neuvonen,et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.
[76] Manfred Kansy,et al. Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model , 2008, Drug Metabolism and Disposition.
[77] U. Hofmann,et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17 , 2005, Pharmacogenetics and genomics.
[78] P. Neuvonen,et al. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide , 2008, Journal of clinical pharmacology.
[79] Hyunyoung Jeong,et al. Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans , 2000, Pharmaceutical Research.
[80] T. Langmann,et al. Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. , 1997, Biochemical and biophysical research communications.
[81] J. Miners,et al. In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. , 2002, British journal of clinical pharmacology.
[82] M. Fromm,et al. Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.
[83] Y. Sugiyama,et al. Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. , 1998, The Journal of pharmacology and experimental therapeutics.
[84] Y. Sugiyama,et al. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. , 2004, Molecular pharmacology.
[85] J. Houston,et al. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. , 1995, The Journal of pharmacology and experimental therapeutics.
[86] K. Maeda,et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.
[87] J. Houston,et al. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[88] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[89] J. Houston,et al. In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[90] M. Niemi,et al. Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans , 2007, Pharmaceutical Research.
[91] P. Neuvonen,et al. Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.
[92] Junjeong Choi,et al. Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans , 2008, Clinical pharmacology and therapeutics.
[93] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[94] K. Maeda,et al. INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS , 2006, Drug Metabolism and Disposition.
[95] Y. Sugiyama,et al. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. , 1999, The Journal of pharmacology and experimental therapeutics.
[96] D. Greenblatt,et al. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. , 2000, The Journal of pharmacology and experimental therapeutics.
[97] J. Houston,et al. Effect of Omeprazole on Diazepam Disposition in the Rat: in Vitro and in Vivo Studies , 1995, Pharmaceutical Research.
[98] Y. Sugiyama,et al. Uptake Is the Rate-limiting Step in the Overall Hepatic Elimination of Pravastatin at Steady-state in Rats , 1996, Pharmaceutical Research.
[99] H. Yamazaki,et al. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[100] Robert J Riley,et al. EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE , 2004, Drug Metabolism and Disposition.
[101] C. Crespi. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .
[102] N. Makita,et al. Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access. , 2004, Molecular pharmacology.
[103] Thierry Lavé,et al. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[104] Steffen Bauer,et al. Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.
[105] T. Baillie,et al. Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.
[106] R J Riley,et al. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. , 2006, Current drug metabolism.
[107] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[108] M Baker,et al. Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[109] Diana Kazolias,et al. Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.
[110] Kiyomi Ito,et al. Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes , 2004, Pharmaceutical Research.
[111] Y. Sugiyama,et al. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats , 1985, Journal of Pharmacokinetics and Biopharmaceutics.
[112] T Iwatsubo,et al. PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.
[113] Hannah M Jones,et al. SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.
[114] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[115] Rui Gao,et al. Pharmacogenetics of membrane transporters: a review of current approaches. , 2008, Methods in molecular biology.
[116] D. Jaeck,et al. Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[117] Y. Sugiyama,et al. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.
[118] B. Burchell,et al. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. , 2002, The Journal of pharmacology and experimental therapeutics.
[119] J S Harmatz,et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[120] Y. Sugiyama,et al. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[121] D. Keppler,et al. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1) , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[122] K. Pang,et al. Effect of diffusional barriers on drug and metabolite kinetics. , 1987, Drug metabolism and disposition: the biological fate of chemicals.
[123] Albert P. Li. Overview: hepatocytes and cryopreservation--a personal historical perspective. , 1999, Chemico-biological interactions.
[124] T. Abe,et al. Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.
[125] D. Keppler,et al. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.
[126] Kazuya Maeda,et al. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.
[127] K. Maeda,et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.
[128] T. Yamamoto,et al. High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[129] Peter J H Webborn,et al. Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes , 2008, Drug Metabolism and Disposition.
[130] Y. Sugiyama,et al. Kinetics of hepatic transport of 4-methylumbelliferone in rats. Analysis by multiple indicator dilution method , 1985, Journal of Pharmacokinetics and Biopharmaceutics.
[131] R. Austin,et al. A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.
[132] K. Pang,et al. Theoretic aspects of pharmacokinetic drug interactions , 1977, Clinical pharmacology and therapeutics.
[133] R J Riley,et al. In vitro–in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[134] Y. Sugiyama,et al. Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. , 2003, Drug metabolism and pharmacokinetics.
[135] K. Maeda,et al. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[136] Y. Sugiyama,et al. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. , 1998, The Journal of pharmacology and experimental therapeutics.
[137] M. Nakamura,et al. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[138] K. Nagata,et al. Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. , 2006, Current drug metabolism.
[139] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[140] Yuichi Sugiyama,et al. Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[141] P. Watkins. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation , 1995 .
[142] J. Noordhoek,et al. Influence of administration route and blood sampling site on the area under the curve. Assessment of gut wall, liver, and lung metabolism from a physiological model. , 1983, Drug metabolism and disposition: the biological fate of chemicals.
[143] M. Kato,et al. Intestinal first-pass metabolism of CYP3A4 substrates. , 2008, Drug metabolism and pharmacokinetics.
[144] A. Barve,et al. Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.
[145] S. Wrighton,et al. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*† , 2001, Drug metabolism reviews.
[146] I. Roots,et al. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations , 2008, European Journal of Clinical Pharmacology.